Evidence map›Paper›PMID 23284679›Full record

ArticlePloS one2012

HSD3B and gene-gene interactions in a pathway-based analysis of genetic susceptibility to bladder cancer.

Angeline S Andrew, Ting Hu, Jian Gu, Jiang Gui, Yuanqing Ye, Carmen J Marsit, Karl T Kelsey, Alan R Schned, Sam A Tanyos, Eben M Pendleton and 7 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Integrative Analysis ofInternational journal of molecular sciences · 2025
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Angeline S AndrewNorris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, United States of America.
Ting Hu
Jian Gu
Jiang Gui
Yuanqing Ye
Carmen J Marsit
Karl T Kelsey
Alan R Schned
Sam A Tanyos
Eben M Pendleton
Rebecca A Mason
Elaine V Morlock
Michael S Zens
Zhongze Li
Jason H Moore
Xifeng Wu
Margaret R Karagas
Dartmouth College · USDartmouth Hospital · GBThe University of Texas MD Anderson Cancer Center · USJohn Brown University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Vanessa Jensen · 1985 to 2026
$290.8M
Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
VARIATION IN BIOACCUMULATION AND BIOMAGNIFICATION OF METALS IN NORTHERN US LAKESP42ES007373 · NIEHS · DARTMOUTH COLLEGE · PI CHEN, CELIA Y · 1995 to 2019
$52.0M
Translational Research Support CoreP30ES000002 · NIEHS · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI SUSAN A KORRICK · 1985 to 2026
$44.6M
Targeting Ral GTPases in Bladder CancerP50CA091846 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DINNEY, COLIN P.N., MCCONKEY, DAVID J. · 2001 to 2018
$37.4M
THE ROLE OF CAL IN CIF-MEDIATED DEGRADATION OF CFTRP20RR018787 · NCRR · DARTMOUTH COLLEGE · PI STANTON, BRUCE A. · 2003 to 2011
$21.9M
VANADIUM AND HUMAN HEALTHP42ES005947 · NIEHS · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI KELSEY, KARL TIMOTHY · 1992 to 2006
$19.6M
NONMELANOMA SKIN CANCER IN NEW HAMPSHIRER01CA057494 · NCI · DARTMOUTH COLLEGE · PI KARAGAS, MARGARET RITA · 1993 to 2015
$10.9M
Quantitative Biology Research InstituteP20GM103534 · NIGMS · DARTMOUTH COLLEGE · PI AMOS, CHRISTOPHER I. · 2012 to 2016
$8.6M
The Boston Collaborative Oral Cancer StudyR01CA078609 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI KELSEY, KARL TIMOTHY · 1999 to 2010
$5.3M
Genome-Wide Association Analysis of Bladder CancerU01CA127615 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WU, XIFENG · 2008 to 2012
$5.1M
MOLECULAR EPIDEMIOLOGY OF NON-MELANOMA SKIN CANCERR01CA082354 · NCI · UNIVERSITY OF MINNESOTA · PI NELSON, HEATHER HAMMOND · 1999 to 2011
$4.2M
NCI NIH HHS CA078609NCI NIH HHS CA099500NCI NIH HHS CA102327NCI NIH HHS CA121382NCI NIH HHS CA57494NCI NIH HHS CA82354NCI NIH HHS K07 CA102327NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA023108NCI NIH HHS P50 CA091846NCI NIH HHS P50 CA 91846NCI NIH HHS R01 CA057494NCI NIH HHS R01 CA074880NCI NIH HHS R01 CA078609NCI NIH HHS R01 CA082354NCI NIH HHS R01 CA 131335NCI NIH HHS R01 CA131335NCI NIH HHS R01 CA 74880NCI NIH HHS R03 CA099500NCI NIH HHS R03 CA121382NCI NIH HHS U01 CA 127615NCI NIH HHS U01 CA127615NCRR NIH HHS P20 RR018787NCRR NIH HHS P20 RR024475NCRR NIH HHS RR018787NCRR NIH HHS RR024475NCRR NIH HHS RR028309NIEHS NIH HHS 5 P42 ES05947NIEHS NIH HHS ES00002NIEHS NIH HHS ES07373NIEHS NIH HHS P30 ES000002NIEHS NIH HHS P42 ES005947NIEHS NIH HHS P42 ES007373NIGMS NIH HHS GM103534NIGMS NIH HHS P20 GM103534NLM NIH HHS LM009012NLM NIH HHS R01 LM009012
6 · The paper itself

Abstract

Bladder cancer is the 4(th) most common cancer among men in the U.S. We analyzed variant genotypes hypothesized to modify major biological processes involved in bladder carcinogenesis, including hormone regulation, apoptosis, DNA repair, immune surveillance, metabolism, proliferation, and telomere maintenance. Logistic regression was used to assess the relationship between genetic variation affecting these processes and susceptibility in 563 genotyped urothelial cell carcinoma cases and 863 controls enrolled in a case-control study of incident bladder cancer conducted in New Hampshire, U.S. We evaluated gene-gene interactions using Multifactor Dimensionality Reduction (MDR) and Statistical Epistasis Network analysis. The 3'UTR flanking variant form of the hormone regulation gene HSD3B2 was associated with increased bladder cancer risk in the New Hampshire population (adjusted OR 1.85 95%CI 1.31-2.62). This finding was successfully replicated in the Texas Bladder Cancer Study with 957 controls, 497 cases (adjusted OR 3.66 95%CI 1.06-12.63). The effect of this prevalent SNP was stronger among males (OR 2.13 95%CI 1.40-3.25) than females (OR 1.56 95%CI 0.83-2.95), (SNP-gender interaction P = 0.048). We also identified a SNP-SNP interaction between T-cell activation related genes GATA3 and CD81 (interaction P = 0.0003). The fact that bladder cancer incidence is 3-4 times higher in males suggests the involvement of hormone levels. This biologic process-based analysis suggests candidate susceptibility markers and supports the theory that disrupted hormone regulation plays a role in bladder carcinogenesis.

Indexed as

Epistasis, GeneticAdultAgedCase-Control StudiesFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedMultienzyme ComplexesPolymorphism, Single NucleotideProgesterone ReductaseSignal TransductionSteroid IsomerasesUrinary Bladder Neoplasms3 beta-hydroxysteroid oxidoreductase-delta(5) 3-ketosteroid isomeraseMultienzyme ComplexesProgesterone ReductaseSteroid Isomerases

Identifiers

PMID23284679
PMCPMC3526593
OpenAlexW2086482109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.